This article was originally published in The Gray Sheet
Firm combines its vascular and cardiac surgery businesses on April 11 to support "the convergence of cardiovascular specialties focused on applying both surgical and minimally invasive approaches to patient care," says Scott Ward, head of the new business. The new entity, Medtronic CardioVascular, will focus on devices that treat coronary artery, vascular and structural heart diseases. Combined revenue will approximate $1.9 billion in 2007. The restructuring may cause a "modest" reduction in jobs, the firm says, but it does not plan facility changes...
You may also be interested in...
More patent-related turbulence appears ahead for Novartis’s sacubitril/valsartan combination in India, with Torrent emerging as the new challenger. The companies are engaged in a legal battle and the Indian firm is also seeking a revocation of the patent on the star heart failure treatment.
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Among the largest gaps in safety data is non-clinical research on CBD use's effect on developing fetus and adolescent brain, in utero/lactational exposure, reproductive toxicity and the potential for a latency period before toxicity, says FDA neuroscientist Andrew Shen.